EC Approves Menarini and NewAmsterdam's Ubeslo and Evlarco
- European Commission grants marketing authorization for Ubeslo and Evlarco
- Obicetrapib represents a new class of CETP inhibitor therapy
- Approval follows a positive CHMP opinion issued on 24 July 2026
- Combination therapy Evlarco pairs obicetrapib with ezetimibe
- Drugs target patients failing to reach LDL-C goals with standard statins
The European Commission has officially granted marketing authorisation for two new cholesterol-lowering medications, Ubeslo and Evlarco, developed by NewAmsterdam Pharma in collaboration with the Menarini Group. This regulatory milestone, confirmed on Monday, 21 September 2026, provides a fresh pharmacological pathway for patients who struggle to manage their low-density lipoprotein cholesterol (LDL-C) levels despite existing treatments.
The approval covers the entire European Economic Area, allowing for the immediate commercial rollout of these therapies across member states.
Industry analysts suggest that the introduction of these drugs addresses a critical gap in lipid management, particularly for those who do not respond adequately to statins or who experience severe side effects from current high-intensity lipid-lowering regimens.
- Ubeslo is approved as a monotherapy containing obicetrapib.
- Evlarco is a fixed-dose combination therapy pairing obicetrapib with ezetimibe.
The decision follows a rigorous assessment period that began with a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) on 24 July 2026, which recommended the authorisation based on clinical evidence of the drug's efficacy and safety profile.
For millions of Europeans living with hypercholesterolaemia, this represents the first major expansion of available oral, once-daily treatment options in several years.
The regulatory framework in Europe remains one of the strictest globally, and the successful navigation of this process by the two companies signals a high confidence level in the trial data submitted to the European Medicines Agency (EMA).
The Mechanism of Obicetrapib in Lipid Regulation
At the heart of these new medications lies obicetrapib, a potent, selective cholesteryl ester transfer protein (CETP) inhibitor.
While past attempts to target the CETP pathway in the early 2000s faced significant setbacks due to a lack of cardiovascular benefit or safety concerns, obicetrapib has been engineered to provide a more precise and effective response.
Medical experts explain that the drug works by inhibiting the CETP protein, which effectively increases high-density lipoprotein (HDL) levels while simultaneously reducing LDL-C.
By modulating these lipid fractions, the medication aims to reduce the overall atherogenic potential of a patient's blood profile.
Unlike traditional statins, which primarily function by inhibiting the HMG-CoA reductase enzyme in the liver to block cholesterol production, obicetrapib acts through a different biological channel.
This makes it a viable candidate for combination therapy, as evidenced by the Evlarco formulation.
By pairing the CETP inhibitor with ezetimibe—which prevents cholesterol absorption in the small intestine—the combination therapy provides a dual-action approach that hits cholesterol production and absorption simultaneously.
Clinical researchers have observed that this combination can lead to a more profound drop in LDL-C than either drug could achieve alone.
The physiological impact is significant: by lowering LDL-C levels more effectively, the risk of plaque build-up in the arteries is reduced, potentially lowering the incidence of major adverse cardiovascular events (MACE) in high-risk populations.
The precision of this mechanism is what sets it apart from older, less specific therapies that often resulted in off-target effects.
Strategic Partnership Between Menarini and NewAmsterdam Pharma
The collaboration between the Menarini Group and NewAmsterdam Pharma has been instrumental in bringing these treatments to the European market.
Menarini, an Italian pharmaceutical giant with a significant distribution network across Europe, provides the commercial muscle needed to ensure that these drugs reach pharmacies and hospitals in a timely manner.
NewAmsterdam Pharma, based in the Netherlands, has focused on the scientific development and clinical testing phases of the obicetrapib molecule.
Industry observers noted that this partnership combines the agility of a focused biotech firm with the established market presence of a traditional pharmaceutical leader.
The agreement, which involves regional licensing, allows Menarini to manage the regulatory and commercial strategy for these products within the European region.
Officials confirmed that this arrangement was designed to ensure that patients across diverse healthcare systems—from the public hospitals in Spain to the private clinics in Germany—have access to the medication once it hits the market.
The strategic importance of this launch cannot be overstated, as the cardiovascular market in Europe remains highly competitive and heavily regulated.
By leveraging Menarini's existing infrastructure, NewAmsterdam Pharma can focus on further research and potential label expansions for obicetrapib without the immediate burden of building a massive, continent-wide sales force from scratch.
This division of labour is becoming a standard model for successful drug commercialisation in the modern European landscape.
Clinical Evidence Supporting the Regulatory Approval
The path to the 21 September 2026 approval was paved by extensive clinical trial data that demonstrated both the safety and efficacy of obicetrapib.
According to regulatory filings, the data presented to the CHMP included results from various Phase 3 studies that evaluated the drug's performance in patients with established cardiovascular disease or those with heterozygous familial hypercholesterolaemia.
The results showed a consistent reduction in LDL-C levels, with many patients achieving their target lipid goals within 12 to 24 weeks of starting treatment.
Safety data was equally scrutinised by regulators, with the incidence of adverse events being comparable to placebo in several key cohorts.
- The trial participants showed a mean reduction in LDL-C levels of approximately 40% when using the combination therapy.
- Long-term tolerability data indicated that the drug was well-tolerated by the majority of patients, with minimal reports of muscle-related side effects often associated with statin use.
These findings were critical in convincing the European Commission that the benefit-risk balance was favourable for the general population of patients with high cardiovascular risk.
Clinical investigators noted that the ability to offer a non-statin-based oral option is a major victory for patients who have previously been labelled as 'statin-intolerant'.
The data also suggested that the once-daily dosing regimen improves patient adherence, which is a major hurdle in the long-term management of chronic conditions like hypercholesterolaemia.
By simplifying the treatment plan, the healthcare system may see a reduction in the complications associated with poorly managed cholesterol levels.
Impact on Cardiovascular Care for European Patients
For the average patient in Europe, the availability of Ubeslo and Evlarco represents more than just another pill on the shelf; it signifies a shift toward personalised cardiovascular management.
Physicians now have a broader toolkit to address the specific needs of patients who remain at risk despite being on maximal tolerated doses of statins.
Cardiologists have long voiced concerns about the limitations of current cholesterol therapies, particularly the ceiling effect seen with statins.
With the introduction of obicetrapib, clinicians can now target the cardiovascular risk profile from a different angle, potentially preventing thousands of heart attacks and strokes across the continent.
The economic impact on healthcare systems is also being evaluated, as effective lipid-lowering therapies are known to reduce the long-term costs associated with cardiovascular hospitalisations.
Healthcare officials are currently working on pricing and reimbursement strategies to ensure that these drugs are accessible to those who need them most.
While the initial rollout will be focused on specialist cardiac clinics, the expectation is that these drugs will eventually be prescribed by general practitioners as well.
The shift toward these newer, more targeted therapies reflects a broader trend in European medicine: moving away from a 'one-size-fits-all' approach towards more nuanced, patient-specific care plans.
Patients are encouraged to discuss their lipid profiles with their healthcare providers to determine if these new therapies are appropriate for their specific cardiovascular risk profile.
The Future Landscape of Lipid-Lowering Therapies
Looking ahead, the approval of obicetrapib-based therapies is likely to spark further innovation in the field of lipidology.
With the success of this CETP inhibitor, researchers are already looking at other potential applications, including the treatment of metabolic disorders or other conditions where lipid regulation is a factor.
The European market, known for its stringent requirements, will continue to serve as a benchmark for the global pharmaceutical industry.
As more data emerges from real-world use, the understanding of how these drugs interact with other medications will grow, providing a more complete picture of their long-term clinical utility.
Menarini and NewAmsterdam Pharma are expected to continue monitoring the performance of these drugs through post-marketing surveillance, ensuring that safety standards remain high as the patient base expands.
The success of this regulatory process highlights the importance of open communication between pharmaceutical developers and European regulatory bodies.
As medical science advances, the focus will likely remain on developing therapies that are not only effective but also easy for patients to integrate into their daily lives.
The 21 September 2026 approval serves as a reminder that even in a crowded market, there is always room for innovation that addresses the unmet needs of patients.
The next phase will involve the integration of these drugs into national clinical guidelines, a process that will be watched closely by the medical community across all member states.